Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Progenics Pharmaceuticals Inc. PGNX

Healthcare Biotechnology
"Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate... see more

Recent & Breaking News (NDAQ:PGNX)

Progenics Announces Offer to Acquire EXINI

GlobeNewswire October 13, 2015

Data From Phase 2 Study of Progenics' 1404 Imaging Agent Presented at EANM Congress 2015

GlobeNewswire October 12, 2015

Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015

GlobeNewswire October 12, 2015

Progenics Pharmaceuticals to Host Research and Development Day on October 1, 2015

GlobeNewswire September 24, 2015

Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR®

Canada NewsWire September 8, 2015

Progenics Pharmaceuticals Announces Second Quarter 2015 Financial Results

GlobeNewswire August 6, 2015

Progenics Pharmaceuticals Announces Exclusive Worldwide Licensing Agreement With Johns Hopkins University for Agent to Image Prostate Cancer Using PET Scan

GlobeNewswire August 4, 2015

Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

GlobeNewswire July 28, 2015

Progenics Pharmaceuticals Sets Second Quarter Financial Results Call for August 6

GlobeNewswire July 21, 2015

Progenics Pharmaceuticals Announces Plans to Move Forward With 1404 Phase 3 Trial

GlobeNewswire July 7, 2015

Progenics Pharmaceuticals to Present at Cantor Fitzgerald's Inaugural Healthcare Conference

GlobeNewswire June 24, 2015

Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR®

Canada NewsWire June 23, 2015

RELISTOR(R) Receives European Approval for Expanded Indication to Treat All Opioid-Induced Constipation

GlobeNewswire June 3, 2015

Progenics Pharmaceuticals to Present at Jefferies 2015 Healthcare Conference

GlobeNewswire May 27, 2015

Progenics Pharmaceuticals Announces First Quarter 2015 Financial Results

GlobeNewswire May 6, 2015

Progenics Pharmaceuticals Sets First Quarter 2015 Financial Results Call for May 6

GlobeNewswire April 29, 2015

RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

PR Newswire April 24, 2015

Progenics Pharmaceuticals to Present at 14th Annual Needham Healthcare Conference

GlobeNewswire April 8, 2015

Progenics Announces the Initiation of Fuji's Phase 2 Trial for 1404 in Japan

GlobeNewswire April 7, 2015

Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2014 Financial Results

GlobeNewswire March 16, 2015